mutational burden between responders and non-responders overlapped substantially 10 , and the opportunities for therapeutic targeting of this feature to enhance response remain uncertain. Even the most optimal cutoff yields weak sensitivity (74%) and specificity (59.3%) in discriminating potential clinical benefit 13 , limiting the utility of tumor mutational burden as a clinical biomarker for individual patients.
Given the major limitations of mutational burden as a predictive biomarker, additional genomic studies have examined other possible biomarkers and suggested that clonal mutations and neoantigens 14 , mutations and copy number alterations (CNAs) affecting particular genes and signaling pathways [15] [16] [17] [18] [19] , and overall tumor aneuploidy 12, 20 may have additional predictive value for response or resistance to immune checkpoint therapies. However, existing studies have focused on cancer types individually without identifying pan-cancer relationships, have had limited sample sizes, and have used inconsistent computational methods. These limitations have restricted the power of these studies to identify meaningful associations and have likely contributed to difficulties in validating prior findings in independent prospective patient cohorts 21 .
We hypothesized that an expanded and uniformly analyzed cohort of clinically annotated patient samples would provide greater Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain clinical utility. Here we uniformly analyzed whole-exome sequencing (WES) of 249 tumors and matched normal tissue from patients with clinically annotated outcomes to immune checkpoint therapy, including radiographic response, across multiple cancer types to examine additional tumor genomic features that contribute to selective response. Our analyses identified genomic correlates of response beyond mutational burden, including somatic events in individual driver genes, certain global mutational signatures, and specific HLA-restricted neoantigens. However, these features were often interrelated, highlighting the complexity of identifying genetic driver events that generate an immunoresponsive tumor environment. This study lays a path forward in analyzing large clinical cohorts in an integrated and multifaceted manner to enhance the ability to discover clinically meaningful predictive features of response to immune checkpoint blockade.
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
power to detect significant associations between pre-treatment tumor characteristics and response to immune checkpoint therapies. Thus, we gathered raw tumor and germline pre-treatment WES data for tumors from immune-checkpoint-therapy-treated patients in seven published studies (n = 171) 7,8,10,22-25 and combined them with data from 78 newly sequenced pre-treatment tumors. By harmonizing clinical annotations and whole-exome analyses across the 249 samples and multiple cancer types, we aimed to (i) assess the generalizability of prior hypotheses regarding response to immune checkpoint blockade to other histological or drug settings; (ii) apply new computational techniques for inference of tumor biology and immunogenicity; and (iii) determine whether our cohort was of . c, Comparison of tumor mutational burden between patients with complete response (CR) or partial response (PR) and those with progressive disease (PD) (for 'All mutations', P = 0.0005 for CR/PR versus PD, P = 0.0054 for CR/PR versus stable disease (SD), and P = 0.434 for SD versus PD; for 'Nonsynonymous mutations', P = 0.0003 for CR/PR versus PD, P = 0.0063 for CR/PR versus SD, and P = 0.38 for SD versus PD; for 'Clonal nonsynonymous mutations', P = 0.00005 for CR/PR versus PD, P = 0.011 for CR/PR versus SD, and P = 0.15 for SD versus PD). Outlying points from patients with > 101 mutations/Mb are not shown (2 CR/PR, 1 SD, 3 PD). d, Intratumoral heterogeneity across response groups (n = 249 biologically independent samples; P = 0.001 for CR/ PR versus PD, P = 0.51 for CR/PR versus SD). e, Clinical response to immune checkpoint therapy broken down by intratumoral heterogeneity. For c and d, P values were calculated by two-sided Mann-Whitney U test: *P < 0.05, **P < 0.005; ns, not significant. Box plots show the median, first and third quartiles, whiskers extend to 1.5 times the interquartile range, and outlying points are plotted individually.
sufficient size to identify statistically robust associations for specific genetic mediators of selective response.
Results
Consolidation of a clinically annotated cohort of whole-exome sequencing for tumors from patients treated with immune checkpoint blockade. WES from clinically annotated tumor samples with matched germline blood or adjacent normal tissue was available for 314 patients ( Fig. 1a and Supplementary Table 1 ). Standard qualitycontrol measures were taken to ensure adequate power to detect tumor-specific mutations ( Fig. 1a , Methods, and Supplementary  Fig. 1a -c). Our final analysis cohort included 249 patient tumors across six cancer types: melanoma (n = 151), non-small-cell lung cancer (NSCLC) (n = 56), small cell lung cancer (n = 1), bladder cancer (n = 27), head and neck squamous cell carcinoma (HNSCC) (n = 12), anal cancer (n = 1), and sarcoma (n = 1) ( Fig. 1a ). These patients were treated with anti-PD-1 (n = 74), anti-PD-L1 (n = 20), anti-CTLA-4 (n = 145), or a combination of anti-CTLA-4 and either anti-PD-1 or anti-PD-L1 therapies (n = 10). A small minority of patients received anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy in combination with another immunotherapy, targeted therapy, or cytotoxic chemotherapy (n = 7) (Supplementary Table 2 ). Across these 249 samples, the average mean target sequencing coverage was 150-fold for tumor tissue and 119-fold for matched germline tissue. The mean estimated tumor purity was 58% (range, 10-97%) ( Supplementary Table 1 ).
In selecting a framework to assess clinical response in this study, we encountered multiple patient stratification methods in previous studies of response predictors to immune checkpoint therapy [10] [11] [12] 26 . These methods varied mostly in their treatment of patients with stable disease (SD) by RECIST 1.1 26 , who have minimal to no change in tumor burden following therapy. Applying three existing response definitions to our cohort, we observed substantial differences in patient classification into responder and non-responder groups ( Fig. 1b and Supplementary Table 3 ). Given the evolving viewpoints on classifying response to immune checkpoint blockade 27 , we adopted a conservative method of defining objective response (OR) as complete response (CR) or partial response (PR) by RECIST (major decrease in tumor burden following treatment) and no response (NR) as progressive disease (PD) by RECIST (major increase in tumor burden following treatment) for the main analyses. Patients with stable disease were considered separately, and analyses using two other response definitions 10,12 that stratify patients with stable disease into those with objective response versus no response by duration of overall survival (OS) or progressionfree survival (PFS) are available in the Supplementary Information.
Mutational burden and response to immune checkpoint therapy.
In examining whole-exome genetic features in this cohort, we began with tumor mutational burden, as this has been the most widely reproduced association with response to immune checkpoint therapy. We found that, in this combined cohort, patients with complete or partial response had significantly higher tumor mutational burdens than patients with progressive disease (P < 0.05 for all, Mann-Whitney U test) ( Fig. 1c ). This finding persisted within cancer types ( Supplementary Fig. 2 ) and was particularly prominent in patients treated with PD-1or PD-L1 inhibitors ( Supplementary  Fig. 3a ). Patients with stable disease tended to have mutational burdens intermediate between those of patients with progressive disease and those with complete or partial response, with higher mutational loads in patients with stable disease with long compared to short duration of overall survival ( Supplementary Fig. 3b ).
While these findings are consistent with the growing body of literature supporting the association between mutational burden and immune checkpoint therapy response, we noted that the ranges of the mutational burdens for the response groups overlapped considerably ( Fig. 1c ), and we found that tumor mutational burden had poor predictive power to differentiate complete or partial response from progressive disease as a single variable in this cohort (area under the receiver operator characteristic (ROC) curve (AUC) = 0.66) ( Supplementary Fig. 4 ). In attempts to build upon the utility of tumor mutational burden as a predictive variable for response to immune checkpoint therapy, past studies have determined that clonal mutations (found in every cancer cell) rather than subclonal mutations (found in a subset of cancer cells) are more strongly associated with response in lung adenocarcinomas and some melanomas, potentially owing to stronger T cell responses to neoantigens generated from clonal versus subclonal mutations 14 .
We queried our cohort for this association by using ABSOLUTE to infer mutational clonality (Methods) and demonstrated that clonal nonsynonymous mutational burden strongly predicted complete or partial response versus progressive disease across cancer types and response categorizations (Fig. 1c,d and Supplementary  Fig. 2 ). Patients with a large proportion of subclonal mutations (> 50%), which we term high intratumoral heterogeneity, were substantially more likely to have progressive disease than complete or partial response across all tumors described here (P = 0.0014, Fisher's exact test) ( Fig. 1e ). Thus, while mutational burden begins to explain the variance in patient response to immune checkpoint therapies, intratumoral heterogeneity contributes additional biological insight.
Mutations in specific genes associated with response or resistance to immune checkpoint therapy. Given the complexity we observed in the association between mutational load and response to immune checkpoint therapy, we pursued additional analyses of exome-level features that could provide further nuance to this association. We next investigated whether somatic mutations in specific genes were associated with response to immune checkpoint therapy, hypothesizing that this analysis would identify genes driving biological processes generating large numbers of mutations or those creating an immunoresponsive phenotype independently of mutational burden.non-clinically annotated NSCLC exomes Given that response rates were similar across all cancer types ( Supplementary Table 3 ), we first compared nonsynonymous mutations in patients with complete or partial response to those in patients with progressive disease across all genes; however, the associations found were too weak to pass correction for multiplehypothesis testing ( Supplementary Fig. 5 ). Thus, we limited our analysis to known hotspot mutations in cancer driver genes and to loss-of-function alterations in known tumor suppressors (Methods and Supplementary Table 4 ), as these events are more likely to have a significant impact on tumor biology. Clonal driver alterations in PIK3CA, KRAS, and PBRM1 were enriched in patients with complete or partial response, while clonal driver mutations in EGFR were enriched in patients with progressive disease (two-tailed Fisher's exact test, P < 0.05 for all genes; Benjamini-Hochberg false discovery rate (FDR) q = 0.18 for KRAS and PIK3CA) ( Fig. 2a ). After correcting for tumor mutational burden, KRAS and PIK3CA remained associated with complete or partial response (P < 0.05, logistic regression) ( Fig. 2b ), although these observations did not pass FDR correction and may be confounded by additional aspects of a tumor's genetic profile.
Driver mutations within a given gene may occur in different functional domains and have different phenotypic effects, often depending on the cancer context. Thus, we next examined these cohort-wide gene associations for trends within specific cancer types. Of the patients with clonal hotspot mutations in PIK3CA, those with complete or partial response had melanoma, HNSCC, anal cancer, or bladder cancer, whereas the majority of those with stable or progressive disease had lung cancer ( Fig. 2c , Supplementary Fig. 6 , and Supplementary Table 5 ). Hotspot mutations in KRAS occurred predominantly in patients with complete or partial response across multiple cancer types ( Fig. 2d ). Genetic events in PIK3CA and KRAS were too infrequent to fully clarify their relationships to response in this study, but these results demonstrate that single-gene associations with response to immune checkpoint therapy can provide additional information beyond mutational burden, in a manner that may be dependent on or independent of cancer type.
Despite combining data from multiple studies and cancer types, our analyses were still statistically underpowered to detect important relationships; thus, we sought to estimate the sample sizes needed for discovery of single-gene correlates of response with appropriate correction for multiple-hypothesis testing (Methods). We modeled statistical significance values for common or rare variants associated with complete or partial response versus progressive disease at various sample sizes ( Fig. 2e ). In the best-case scenario, where a variant is both relatively common (~10% prevalence) and specific to responders, sample sizes of around 300 would be adequate to detect significant associations. Meanwhile, detection of rare responseassociated variants (~1% frequency), even if highly specific, would Supplementary Fig. 6 ). e, Simulated statistical power calculation for detection of responseassociated genes. The significance of association between response and the presence of a mutation in a gene (two-tailed Fisher's exact test) is shown on the y axis for varying sample sizes (x axis). Colors represent the frequency of mutations and the specificity of alterations to OR versus NR. The dashed horizontal line represents Bonferroni-corrected P = 0.05 after correcting for multiple comparisons over the 116 cancer driver genes assessed in this study. The simulated cohort contained 40% patients with CR/PR and 60% patients with PD.
necessitate sample sizes in the thousands. Thus, continuing to combine independent clinically annotated cohorts will aid in increasing statistical power to detect common response-associated variants, but for detection of rarer events, applying insights from experimental studies for hypothesis-driven validation will be a crucial adjunct.
Integrated analysis of response-and resistance-associated mutations with mutational signatures. As a further step toward understanding the mutational processes that generate an immunoresponsive tumor environment, we next investigated whole-exome signatures of mutagenic biological processes. We used a previously described non-negative matrix factorization technique to identify known mutagenic processes in lung cancer, melanoma, bladder cancer, and HNSCC 28, 29 (Methods). Using this technique, the somatic mutations within a tumor are probabilistically assigned to underlying mutational signatures, which are patterns of somatic mutations thought to arise from carcinogenic processes (for example, a predominance of C-to-A transversions in tobacco-smokingassociated cancers or C-to-T transitions in UV-light-associated tumors) ( Supplementary Tables 6 and 7 ). As has been seen previously in analyses of non-clinically annotated NSCLC exomes 30 , pre-treatment lung tumors in this cohort with a high proportion of smoking-associated mutations tended to have low intratumoral heterogeneity, high mutational burden, and frequent KRAS mutations ( Fig. 3a -c). The proportion of smoking-associated mutations was also higher in patients with complete or partial response than in those with progressive disease ( Supplementary Fig. 7a ). Meanwhile, tumors with EGFR hotspot mutations trended toward enrichment in subclonal mutations (P = 0.035), had low mutational burdens, were over-represented in never-smokers (two-tailed Fisher's exact test, P = 0.00017), and had generally poor responses to immune checkpoint therapy ( Fig. 3a,d ), which is also consistent with previously published results 31, 32 . Thus, the association between KRAS and EGFR mutation status and response to immunotherapy ( Fig. 2a,b ) may be related not only to mutational burden but also to mutational signature and mutational clonality. After controlling for smoking history, mutational burden remained a significant predictor of response ( Fig. 3e and Supplementary Fig. 7b ). Concurrent consideration of mutational signatures, clonal architecture, and hotspot mutations in NSCLC enhances understanding of somatic mediators of immunotherapy response and resistance. We also examined mutational signatures in melanoma tumors, which are dominated by exposure to UV light (S7), prior chemotherapeutic treatment with alkylating agents (S11), and other signatures not clearly associated with specific environmental exposures (S1 and S5). Dominant mutational signature explained a large proportion of the variance in mutational burden and was highly correlated with intratumoral heterogeneity ( Fig. 4a and Supplementary  Fig. 8a ). After stratifying by dominant mutational signature, no significant difference in mutational burden was observed between patients with complete or partial response and those with progressive disease (P > 0.05 for all) (Fig. 4b) . The non-UV/non-alkylating group had a higher proportion of patients with progressive disease than the other two groups ( Fig. 4c ) and was composed largely of mucosal, uveal, and acral lentiginous melanomas, although dominant mutational signature and histology did not overlap perfectly ( Supplementary Fig. 8b ). The observation that mutational load is not a significant predictor of response after correcting for dominant mutational signature in melanoma raises the possibility that, in this cancer type, mutational burden itself may not directly mediate response but rather may serve as a proxy for an underlying biological process that both increases tumor immunogenicity and promotes accumulation of somatic mutations.
In bladder cancer and HNSCC, similar analyses demonstrated association of APOBEC-associated signatures (S2 and S13) with higher mutational burdens (P = 0.002 for bladder cancer, P = 0.03 for HNSCC, two-sided Mann-Whitney U test) and greater likelihood of complete or partial response (P = 0.019) ( Fig. 4d-g) . APOBEC signatures have been linked with tobacco exposure 33 , but viral infection and PIK3CA hotspot mutations are other potential etiologies 34 . These correlations may contribute to and/or confound the observed association between PIK3CA hotspot mutations and complete or partial response described above ( Fig. 2c and Supplementary Fig. 6 ). APOBEC mRNA expression has also previously been associated with increased PD-L1 immunohistochemical staining 35 and high tumor mutational burden 36 in urothelial carcinoma. Overall, genetic features-including mutational burden, intratumoral heterogeneity, tumor driver mutations, and mutational signatures-appear to have interrelated associations with response in this cohort. Determining which of these features ultimately drives response to immune checkpoint therapy in these patients will require further clinical and experimental study.
Copy number alterations associated with response or resistance to immune checkpoint therapy. In addition to somatic mutations, CNAs may also contribute to selective response, and CNAs affecting the interferon-γ pathway have been implicated in intrinsic resistance to immune checkpoint therapies in melanoma 17 . In this cohort, we assessed CNAs expected to interfere with interferon-γ signaling after correcting for tumor purity (Methods), which can strongly influence the number of called CNAs in cohorts with heterogeneous tumor purity and ploidy ( Supplementary Fig. 9a -c). After correcting for tumor purity, interferon-γ -related CNA events were more infrequent than previously described, but consistent with prior studies these events were enriched in patients with progressive disease in comparison to those with complete or partial response (19/123 versus 3/70; P = 0.019, Fisher's exact test) ( Fig. 5a ). This relationship persisted within cancer types and therapy classes, although this study was insufficiently powered to detect a significant association in many of the subgroup analyses (Fig. 5b,c and Supplementary Figs. 10 and 11).
Next, we analyzed focal CNAs affecting 63 commonly amplified and deleted tumor suppressors and oncogenes (Methods and  Supplementary Tables 8 and 9 ) to nominate additional mediators of selective response or resistance. While these events were rare and no gene achieved statistical significance alone, amplifications of PAK1, YAP1, and CCND1 on chromosome 11q and amplifications of MDM2 and CDK4 on chromosome 12q were seen predominantly in patients with progressive disease (Fig. 5d) , with the latter of note as CDK4/CDK6 inhibition was recently associated with increased tumor immunogenicity 37 . Additionally, homozygous PTEN deletion occurred exclusively in patients with intrinsic resistance to immune checkpoint therapy (n = 4 with progressive disease; P = 0.30) ( Fig. 5d ), recapitulating the observation of biallelic PTEN loss in resistance to immunotherapies in prior clinical and experimental studies 23, 38 . Clonal biallelic loss of PTEN via truncating mutation was not as clearly associated with progressive disease, although many of these events were splice-site mutations of uncertain biological significance (Fig. 5e ). Truncating PTEN mutations were also seen in resistant tumors from patients with tumor shrinkage following anti-CTLA-4 therapy at other sites, although these patients were excluded from the main analysis owing to their mixed clinical response ( Supplementary Fig. 12 and Supplementary  Table 1 ). Thus, both mutations and CNAs can influence response to immune checkpoint therapy by activating or suppressing pathways that interact with tumor-immune signaling, although our analyses indicate that these features are elaborately interrelated and require substantially increased cohort size and mechanistic validation for robust interpretation.
Validation of previously described response predictors for immune checkpoint therapies. Previous studies have identified additional pathways and genes associated with response or resistance to immune checkpoint therapy, which were not identified via the unbiased analyses presented thus far, potentially owing to insufficient power after correcting for multiple-hypothesis testing. We attempted a focused validation of the previous findings in this cohort, beginning with an analysis of loss-of-function alterations in PBRM1, a member of the PBAF form of the SWI/SNF complex. Prior work in clear-cell renal cell carcinoma (ccRCC), a cancer type not represented in this study, demonstrated that biallelic PBRM1 loss correlates with response to anti-PD-1or anti-PD-L1 therapy, while mutational load does not 19 . Additional functional data in melanoma have supported this association and implicated other related genes in the SWI/SNF family of chromatin remodelers 39 . In this cohort, truncating mutations in PBRM1 and other related epigenetic regulators in the SWI/SNF complex were also over-represented in responders, with biallelic loss events occurring almost exclusively in the tumors from patients with complete or partial response (Figs. 2a,b and 5f , and Supplementary Fig. 13 ). Other mutations that have previously been described in association with acquired resistance to immune checkpoint therapies include JAK-STAT pathway mutations and alterations in antigen-presentation machinery (for example, β 2-microglobulin and tapasin) 40, 41 . Lossof-function mutations and deletions in these pathways were rare in this cohort ( Supplementary Fig. 14a-c) , perhaps reflecting differences in genetic mechanisms of intrinsic versus acquired resistance, and further work is required to determine the functional significance of these variants.
Neoantigens associated with response to immune checkpoint therapy. Given the complexities of computationally assessing the impact of oncogenic pathway alterations and tumor mutational burden on response to immune checkpoint therapy, we lastly examined mutations that could more directly influence tumor-immune interactions by generating tumor-specific neoantigens that induce a T cell-mediated antitumor response 42 . We inferred neoantigens in silico (Methods and Supplementary Table 10 ) and found that, on average, each nonsynonymous mutation generated 2.24 predicted neoantigens, with extremely high correlation between nonsynonymous mutational burden and neoantigen burden across patients (R 2 = 0.99, P < 0.00001) (Fig. 6a ), making it difficult to disentangle the effects of mutational versus neoantigen burden on response using in silico methods alone.
Recent studies have demonstrated that personalized cancer vaccines targeting neoantigens specific to an individual's tumor can lead to durable clinical benefit alone or in concert with immune checkpoint blockade therapies 43, 44 . More than 99% of the predicted neoantigens in this study arose from passenger mutations, which occur throughout the exome, are frequently found in subclonal tumor populations, and are largely unique to each patient's tumor. However, 871 predicted neoantigens were generated by driver mutations, and 8 of these 'driver' neoantigens occurred recurrently in patients with complete or partial response but not in patients with progressive disease, in a human leukocyte antigen (HLA)dependent manner (Fig. 6b,c) . Additionally, as expected given the known oncogenic effects of the mutations yielding these neoantigens, these eight neoantigens were clonal in all samples, suggesting that a T cell-mediated response, if present, would target all cancer cells 14 . Thus, driver alterations can generate tumor neoantigens and may contribute to provoking an effective immune response to checkpoint blockade therapy in HLA-matched patients, although further experimental study is required to clarify the biological significance of these putative neoantigens.
Discussion
WES and analysis of 249 tumors from patients treated with anti-PD-1/PD-L1 or anti-CTLA-4 therapies suggest that genomic features beyond mutational burden, including genetic driver events, intratumoral heterogeneity, and mutational signatures, may affect response to immune checkpoint blockade. In this work, we combined data from multiple institutions using a standardized computational pipeline and applied a uniform and well-accepted definition of radiographic response to cancer therapy to more robustly assess genetic predictors of response to immune checkpoint therapy. In so doing, we validated past findings and expanded their generalizability to new cancer contexts, discovered new correlative biomarkers of response using a larger sample size with more statistical power, and investigated the relationships between predictive biomarkers in enhanced detail. For instance, biallelic PTEN loss was first clinically described in acquired resistance to anti-PD-1 therapy in metastatic uterine leiomyosarcoma, and these clinical results and previous preclinical findings suggest that it may be relevant to intrinsic resistance and mixed response in metastatic melanoma as well 23, 38 . CNAs leading to loss of intact interferon-γ signaling were previously noted in metastatic melanoma intrinsically resistant to treatment with anti-CTLA-4 agents 40 , but this mechanism may also have relevance to anti-PD-1/PD-L1-treated patients and in additional cancer types. PBRM1 loss was first implicated in increasing tumor intrinsic responsiveness to immune checkpoint therapy in ccRCC 19 , but shared biology from loss of PBRM1 or ARID2-which both encode proteins within the PBAF form of the SWI/SNF complex-in melanoma, lung cancer, bladder cancer, and HNSCC may underlie the similar response association observed here. Notably, experimental descriptions of the mechanistic underpinnings of these genetic variants in influencing response or resistance to T cell-mediated killing have been instrumental in supporting computational results 17, 38, 39 , emphasizing the importance of cross-validation of clinically relevant tumor variants in mechanistically driven investigations.
Such findings show that comprehensive consideration of multiple genomic features may help place existing associations such as mutational burden in a broader biological context. In the melanoma tumors from this study, mutational burden was no longer a significant predictor of response after correcting for dominant mutational signature, a finding that warrants further experimental and translational inquiry. KRAS and EGFR mutations in lung cancer have previously been described as being associated with response and resistance, respectively; this study demonstrates a relationship between these driver mutations and carcinogenic exposures, intratumoral heterogeneity, and mutational burden 7, 32 . The global approach outlined herein will be essential in future investigations of predictors of immune checkpoint therapy response.
Power calculations suggest that combining hundreds or even thousands of clinically annotated patient samples will be necessary to reliably detect specific predictors of response to immune checkpoint therapies. While we preliminarily assessed response predictors specific to anti-CTLA-4 versus anti-PD-1/PD-L1 therapies or within a given cancer type, these findings are biased by the data available from clinically annotated cohorts; anti-CTLA-4 therapies were used predominantly in melanoma and anti-PD-1/PD-L1 therapies dominated most other cancer types. Further studies more directly comparing therapy classes within the same tumor histology, and vice versa, will be necessary, as will consideration of response predictors for combinations of checkpoint inhibitors with or without targeted or cytotoxic chemotherapies. Exceptions to single-feature genomic associations between this study and previous works likely can be explained by complex context-dependent effects and emphasize the need for caution to avoid over-interpretation of results.
While sample size and cohort heterogeneity remain major limitations of this work, this study describes a path forward for gathering insights from multiple clinically annotated patient cohorts. Our work advances hypotheses of biological mechanisms, suggests clinically relevant biomarkers, and highlights the importance of further, larger studies to reliably and robustly identify biomarkers of response and intrinsic resistance to immune checkpoint blockade.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0200-2.
Clinical cohort consolidation. Patients from the Dana-Farber Cancer Institute with metastatic bladder cancer, HNSCC, lung cancer, or melanoma treated with anti-PD-1, anti-PD-L1, anti-CTLA-4, or a combination of these therapies were identified, and pre-treatment tumor tissue and matched germline blood were obtained for genetic sequencing. These studies were conducted in accordance with the Declaration of Helsinki and approved by the Dana-Farber Cancer Institute Institutional Review Board (protocols 11-104, 05-042, 02-180, 09-472, 02-021, and . Electronic medical charts were reviewed to assess best response by RECIST (v1.1), duration of progression-free survival, duration of overall survival, patient demographic characteristics, and other relevant clinical details (for example, smoking history). 'Current/former' smokers were those who reported > 5 pack-years (packs per day × years smoking) of tobacco use. 'Never' smokers were those who reported ≤ 5 pack-years 46 . Clinical information from studies conducted outside the Dana-Farber Cancer Institute was downloaded from online supplementary information 7, 8 . Where overall survival was not reported in these studies, it was censored at progression-free survival.
Response stratification. Patients were divided into objective responder and non-responder groups according to three published response metrics, using best response by RECIST, duration of progression-free survival, and duration of overall survival [10] [11] [12] . For patients in the MSKCC melanoma cohort, all non-responders were presumed to have progressive disease as their best response by RECIST. Tumor samples from progressing lesions from patients who had clinical benefit from immune checkpoint therapy were excluded from the main analysis. Tumors from patients with progression-free or overall survival duration of less than 30 d were excluded from analysis, as these patients may have had disease that was too advanced to experience clinical benefit from immune checkpoint therapy.
DNA extraction and sequencing. For samples newly sequenced from the Dana-Farber Cancer Institute, DNA extraction from formalin-fixed, paraffin-embedded (FFPE) tumor blocks was performed as previously described 47 . Exome sequencing and data processing to produce a BAM file were performed using established analytical pipelines at the Broad Institute 23 .
DNA sequencing quality control. Data from newly sequenced samples were combined with raw sequencing data (BAM files) from previously published cohorts of tumor-normal sequencing from patients with metastatic melanoma 8, 10 , lung cancer 7, 25 , anal cancer 24 , and sarcoma 23 . All 314 samples with tumor and germline sequencing data and clinical annotations were processed through standard quality-control pipelines. Samples with poor sequencing coverage (tumor mean target coverage < 25 × , normal mean target coverage < 15 × ) or high sample contamination 48 in tumor or normal tissue were excluded ( Fig. 1a and Supplementary Table 1 ). Additionally, samples with germline sequencing from adjacent normal tissue were assessed for tumor-in-normal contamination using deTiN 49 and excluded if the normal tissue contained ≥ 1% tumor nuclei ( Fig. 1a and Supplementary Table 1 ). After mutation calling and somatic copy number alteration assessment, tumors with estimated purity below 10% were also excluded 50 ( Supplementary Fig. 1a,b ). These quality-control measures were taken because high sample contamination and low tumor purity can lead to systematic under-calling of somatic SNPs and CNAs and interference with accurate assessment of tumor mutational burden and identification of response-associated molecular features 51 .
Whole-exome analysis. Somatic SNPs were identified by MuTect 51 , with computational filtering of artifacts introduced by DNA oxidation during sequencing 52 or FFPE-based DNA extraction using a filter-based method. Strelka 53 was applied to detect small indels. Annotation of the variants identified was performed using Oncotator (https://software.broadinstitute.org/cancer/ cga/oncotator). Mutational clonality was estimated by ABSOLUTE, which uses the allelic fraction of called mutations and allelic copy number information to determine mutational clonality and overall tumor purity and ploidy 50 . Clonal mutations were defined as those with estimated cancer cell fraction (CCF) of 1 or those whose probability of being clonal exceeded the probability of being subclonal. Nonsynonymous mutational burden was normalized by megabases covered at adequate depth to detect variants with 80% power using MuTect given estimated tumor purity by ABSOLUTE (Supplementary Table 1 ). The number of bases covered at a given depth threshold in the tumor sample was determined using the GATK DepthOfCoverage module. Putative driver mutations were collected using cBioPortal standards 54, 55 , including both 3D hotspots in tumor suppressors and oncogenes 56 and any loss-of-function variant in a tumor suppressor.
For copy number analysis, copy ratios were calculated for each captured target by dividing the tumor coverage by the median coverage obtained in a set of reference normal samples. The resulting copy ratios were segmented using the circular binary segmentation algorithm 57 . Segments were considered amplified or deleted if the |log 2 (copy ratio)| exceeded 0.5 ( Supplementary Fig. 9a ). For samples with uniform sample purity and ploidy, this definition of amplifications and deletions is adequate to detect CNAs. However, in this sample of tumors, called CNAs were heavily influenced by sample purity (Supplementary Fig. 9a ).
The |log 2 (copy ratio)| > 0.5 definition was insufficiently sensitive in low-purity samples, which have artificially depressed copy ratios owing to a high proportion of sequencing reads from normal tissue. Conversely, this definition may be excessively noisy in high-purity tumors.
Thus, to correct segment copy ratios for sample purity, segment copy ratios were rescaled by sample purity and ploidy with values derived from ABSOLUTE. Segments were considered amplified or deleted if the |log 2 (purity-corrected copy ratio)| exceeded 0.5. Specifically, the purity-corrected copy ratio was derived by dividing the purity-corrected (or rescaled) total copy number (rCN) for a given segment by the sample ploidy. This procedure yielded improved false negative rates in low-purity tumors and false positive rates in high-purity tumors, such that the proportion of a tumor genome considered amplified or deleted was less closely associated with tumor purity ( Supplementary Fig. 9b ).
However, while using a |log 2 (purity-corrected copy ratio)| > 0.5 definition of deletions and amplifications was effective for detecting large CNAs with high sensitivity, it did not provide adequate specificity for detecting focal events that would be more likely to be genomic driver CNAs for a tumor. Thus, we applied a previously described concept called focality 58 to identify CNAs that were large outliers in copy ratio, representing either homozygous deletions expected to completely eliminate tumor expression of a given gene or amplifications expected to greatly overexpress a gene. In this process, the rescaled copy number (rCN) from ABSOLUTE was used as input. For each segment in a tumor genome, the focality was calculated by considering the fraction of a sample's genome with lower rCN than that segment (for amplified regions) or higher rCN (for deleted regions). Segments were considered deleted if their rCN was < 0.25 and their focality was > 0.995. Segments were considered amplified if their focality exceeded 0.98 -0.2 × log 2 (rCN/5) and highly amplified if their focality exceeded 0.98 -(1/7) × log 2 (rCN/7). The results from this analysis are displayed in Supplementary Fig. 9c ; far fewer segments met the criteria for being called amplifications or deletions under this focality-based definition. This focality-based definition of CNA was applied in Fig. 5 as well as Supplementary Figs. 10-12 to demonstrate putative driver CNAs in genes in the interferon-γ signaling pathway, PTEN, and genes in the SWI/SNF family of chromatin regulators. Genes were considered amplified or deleted if all or part of the gene was in a segment with a called CNA using this focality-based definition. For the interferon-γ analysis, samples were defined as having a CNA affecting interferon signaling if any of the regular interferon genes were deleted or any of the four interferon pathway inhibitors (SOCS1, SOCS3, PIAS1, and PIAS4) harbored high amplifications, as previously described 17 . All gene-level CNAs of interest were manually reviewed.
A similar focality procedure was applied to allelic copy number calls from ABSOLUTE to determine heterozygous deletions and amplifications to identify loss-of-heterozygosity events ( Supplementary Figs. 12 and 13 ).
Mutational signature deconvolution was conducted using a non-negative matrix factorization technique as previously described 29 . Mutational signatures were chosen from those previously described in COSMIC (http://cancer. sanger.ac.uk/cosmic/signatures) (Supplementary Table 6 ). The vectors for the commonly observed mutational signatures for each cancer type were used as input for inference of their contribution to observed mutations. Thus, for example, the signatures selected for melanoma pertained to UV exposure, prior alkylating agents, and other exposures, while those used for mutational signature deconvolution in lung cancer included tobacco exposure.
For neoantigen prediction, the four-digit HLA type for each sample was inferred using Polysolver 59 . Putative neoantigens were predicted for each patient by defining all novel amino acid 9-mers and 10-mers resulting from each somatic nonsynonymous point mutation and determining whether the predicted binding rank-a proxy for predicted binding affinity to the patient's germline HLA alleleswas < 2%. Strong binders had rank < 0.5%, while weak binders had rank between 0.5% and 2%, using NetMHCpan (v3.0) [60] [61] [62] .
Statistical analysis. Assessment of enrichment of binary molecular features (for example, wild-type or mutant gene; CNA present or absent) with response (complete or partial response versus progressive disease) was done with Fisher's exact tests. Assessment of differences in means or medians for a continuous variable between two response groups was done with non-parametric Mann-Whitney U tests unless otherwise specified. Correction for multiple-hypothesis testing was done controlling for FDR by the Benjamini-Hochberg method unless otherwise noted. ROC analyses were done using the pROC and Epi packages in R.
For the power calculation analysis ( Fig. 2e) , correction for multiple-hypothesis testing was modeled with a Bonferroni correction over the 116 genes with known cancer driver status assessed previously. Response rates were set at 40% complete or partial response versus 60% progressive disease, which is a generous estimate for response rate in an unselected population. P values were calculated using Fisher's exact tests comparing the prevalence of mutations in a given gene in complete or partial response versus progressive disease.
The alpha level for all comparisons was 0.05 unless indicated otherwise. All statistical analyses were done in R (v. 
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Experimental design 1. Sample size
Describe how sample size was determined. Sample size was determined by systematic access and analysis of all available cases that met criteria, and represents the largest cohort assembled for this kind of analysis. Throughout the text we note when our power is limited by sample size, and we include a power simulation in Fig 2e where we determine that our sample size is adequate to detect a variant that is enriched in responders if the variant is present at 10% in the population.
Data exclusions
Describe any data exclusions. We gathered whole exome sequencing from patients treated with immunotherapy in published and unpublished samples. Patients were excluded if they did not have reported response to immunotherapy or if they had PFS or OS < 30 days from start of therapy. We further excluded samples that failed sequencing re-alignment, or that failed whole exome sequencing quality control, excluding samples with ≥ 1% tumor in normal contamination, mean target coverage < 25x in tumor and < 15x in normal, tumor sample contamination ≥ 5%, and tumor purity < 10%.
Replication
Describe whether the experimental findings were reliably reproduced.
There were no experimental findings to reproduce.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Our study analyzed genomic determinants of response to immunotherapy by stratifying samples into responders or non-responders. This was a retrospective analysis and as such, did not rely on prospective randomization of samples into experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
As described above, this was a retrospective analysis of correlates of treatment response. Outcomes had already been determined for each sample prior to our analysis, and our subsequent analysis required assigning samples to response groups, making further blinding inappropriate.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
